Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zeprumetostat - Jiangsu Hengrui Medicine Co

Next Previous
Drug Profile

Zeprumetostat - Jiangsu Hengrui Medicine Co

Alternative Names: EBI 2554; SHR-2554; TLN-254

Latest Information Update: 22 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Treeline Biosciences
  • Class Amides; Amines; Antineoplastics; Benzofurans; Ethylamines; Piperidines; Pyrans; Pyridines; Pyridones; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Peripheral T-cell lymphoma
  • Phase III Follicular lymphoma
  • Phase II Adenocarcinoma
  • Phase I/II B-cell lymphoma; Solid tumours
  • Phase I Lymphoma; Multiple myeloma; T-cell lymphoma
  • Discontinued HER2 negative breast cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 16 Sep 2025 Jiangsu HengRui Medicine plans a phase II trial for Non-small cell lung cancer (Late stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in Unknown location (PO, Tablet) in October 2025 (NCT07175220)
  • 02 Sep 2025 Chemical structure information added.
  • 02 Sep 2025 Discontinued - Phase-I/II for Prostate cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in China (PO) (Jiangsu Hengrui Medicine Co pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top